Oncologist最新文献

{"title":"The management of imatinib-associated severe skin rash in gastrointestinal stromal tumor: desensitization therapy and pharmacogenetic investigation.","authors":"Xiaoman Liu, Mengying Pi, Mukai Chen, Shirong Cai, Yulong He, Ke-Jing Tang, Xinhua Zhang, Yanzhe Xia","doi":"10.1093/oncolo/oyaf176","DOIUrl":"https://doi.org/10.1093/oncolo/oyaf176","url":null,"abstract":"<p><strong>Background: </strong>Skin rash is one of the most common imatinib-associated adverse events in patients with gastrointestinal stromal tumors (GISTs), potentially compromising treatment adherence and therapeutic efficacy. This study presents a personalized desensitization management of imatinib-associated severe rash with therapeutic drug monitoring (TDM) and pharmacogenetic investigation.</p><p><strong>Patients and methods: </strong>Among 712 patients with GIST receiving imatinib, 54 patients (7.6%) developed severe skin rash (grade 3: 37 patients, recurrent grade 2: 17 patients) and underwent personalized desensitization treatment. This approach involved a temporary cessation of imatinib and initiation of systemic steroids, followed by reintroduction of imatinib with TDM-assisted gradual dose escalation, while steroids were tapered until discontinuation. Pharmacogenetic analysis was conducted to explore potential genetic susceptibility.</p><p><strong>Results: </strong>Following desensitization therapy for severe rash, the majority of patients (92.6%) successfully resumed imatinib treatment at personalized maintenance doses. Grade 3 rash occurred earlier than recurrent grade 2 rash before desensitization therapy (P = 0.004) and was associated with lower final maintenance doses of imatinib after desensitization (P = 0.010). The final imatinib trough concentrations post-desensitization were significantly lower than those at rash onset (P < 0.001). Pharmacogenetic analysis identified IL-6R rs4129267 as significantly associated with imatinib-associated severe skin rash (odds ratio 1.966, 95% CI, 1.143-3.380, P = 0.015).</p><p><strong>Conclusion: </strong>Personalized desensitization therapy assisted by TDM could effectively manage imatinib-associated severe skin rash. The early onset of grade 3 rash underscored the importance of vigilant monitoring during the initial phase of imatinib treatment. Genetic variant in IL-6R may be involved in rash pathogenesis.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144546213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mitigation and Management of Adverse Events Associated With Amivantamab Therapy.","authors":"Narjust Florez, Nicole R LeBoeuf, Julia Rotow, Jennifer A Marks, Joshua K Sabari, Oscar Arrieta, Clarissa Baldotto, Rahul Gosain, Dianne Zawisza, Stephanie McDonald, Emanuela Dylgjeri, Paul Cifuentes, Beth McLellan, Natasha B Leighl","doi":"10.1093/oncolo/oyaf194","DOIUrl":"https://doi.org/10.1093/oncolo/oyaf194","url":null,"abstract":"<p><p>Amivantamab is a fully human bispecific epidermal growth factor receptor (EGFR)-directed and mesenchymal epithelial transition (MET) receptor-directed antibody. Intravenous amivantamab is approved and recommended by treatment guidelines as a first-line treatment (1L) in combination with lazertinib, as a second-line treatment (2L) in combination with chemotherapy in adults with advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations, and as 2L monotherapy or 1L in combination with chemotherapy in adults with advanced or metastatic NSCLC with exon 20 insertion-mutations. Compared with previous therapies, novel treatments such as amivantamab may be associated with distinct and unique adverse reactions that potentially require optimized prevention and management techniques. Commonly reported adverse reactions associated with amivantamab treatment regimens include cutaneous reactions associated with EGFR inhibition, such as rash, paronychia, and pruritus; those associated with MET inhibition, such as peripheral edema and hypoalbuminemia; and general effects, such as infusion-related reactions. Recommendations are summarized from published guidelines and the authors' clinical experience for the prevention and management of adverse reactions associated with amivantamab. An understanding of the expected adverse events with amivantamab regimens, along with the range of prophylactic and management options available, may facilitate maintenance of ongoing treatment in patients deriving clinical benefit and improve patient quality of life on therapy.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144546212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of anamorelin in patients with metastatic urothelial carcinoma receiving systemic chemotherapy: a randomized controlled study.","authors":"Kunihiro Odagiri, Yoshihisa Mimura, Taku Naiki, Yoshihiko Tasaki, Yosuke Sugiyama, Aya Naiki-Ito, Toshiki Etani, Takashi Nagai, Toshiharu Morikawa, Nobuhiko Shimizu, Maria Aoki, Masakazu Gonda, Takahiro Yasui, Yoko Furukawa-Hibi","doi":"10.1093/oncolo/oyaf167","DOIUrl":"https://doi.org/10.1093/oncolo/oyaf167","url":null,"abstract":"<p><strong>Background: </strong>Cancer cachexia reduces chemotherapy efficacy in patients with metastatic urothelial carcinoma (mUC). Anamorelin improves cancer cachexia by increasing serum insulin-like growth factor 1 (IGF-1). The aim of this study was to evaluate the efficacy and safety of anamorelin in patients with mUC.</p><p><strong>Methods: </strong>A total of 38 patients with mUC who received platinum-based chemotherapy were enrolled in an interventional prospective study. Patients were randomized to anamorelin (Ana; n=20) or control (n=18) groups. The primary endpoint was the change in prealbumin. Secondary endpoints were changes in albumin, IGF-1, body weight, skeletal muscle mass index (SMI), interleukin-6 (IL-6) and median overall survival (mOS).</p><p><strong>Results: </strong>Changes in prealbumin, albumin, body weight, and SMI were similar between groups. Compared to control, serum IGF-1 levels in the anamorelin-treated group were higher after 1-week (p<0.05). Changes in IGF-1 and SMI positively correlated in the anamorelin group (R=0.61, p<0.05). When the anamorelin group was divided into two groups by the median serum IGF-1 level after 1-week (Ana-IGF-1 high and Ana IGF-1 low groups), the SMI in the latter group showed a decreased tendency (p=0.14). The Ana-IGF-1 low group showed significantly higher IL-6 levels (p<0.05) at baseline and significantly shorter mOS compared to the Ana-IGF-1 high group (p<0.05). Treatment-related adverse events were comparable between the two groups (any grade: 100% vs. 100%; grade ≥3: 88.9% vs. 90.0%).</p><p><strong>Conclusion: </strong>Anamorelin was well tolerated in patients with mUC. A higher serum IGF-1 level might be associated with anamorelin efficacy; however, a larger study is needed to confirm this.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144546211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Timing and Clinical Significance of Chemotherapy in Patients with Resected Gastric Adenocarcinoma: A Population-based Cohort Study.","authors":"Di Zhang, Qian Yang, Chunwang Ji, Xue Zhang, Xinyu Song, Zhaodi Nan, Qian Xu, Shulun Nie, Jianyuan Zhou, Jiahui Chu, Liliang Dou, Fan Jiang, Jianqiao Jiao, Qinqin Hu, Xuehui Wu, Song Li, Lian Liu","doi":"10.1093/oncolo/oyaf179","DOIUrl":"https://doi.org/10.1093/oncolo/oyaf179","url":null,"abstract":"<p><strong>Background: </strong>This study was to assess the impact of chemotherapy sequence on the prognosis of patients with gastric cancer (GC) undergoing gastrectomy and identify optimal chemotherapy timing along with potential candidates.</p><p><strong>Patients and methods: </strong>Data on patients who underwent gastrectomy was extracted from Surveillance, Epidemiology, and End Results database. Prognostic factors for overall survival (OS) were assessed using Kaplan-Meier and Cox regression analyses. Treatment strategies were categorized into neoadjuvant chemotherapy (NAC), adjuvant chemotherapy (AC), and perioperative chemotherapy (PC), with subsequent analyses of clinical outcomes. Stable inverse probability of treatment weighting (sIPTW) and subgroup analyses were conducted to evaluate significance of chemotherapy timing.</p><p><strong>Results: </strong>Among 4914 patients, 38.4% received NAC, 45% received AC, and 16.6% received PC. The 5-year OS rates for the entire cohort were 41.2%. Although no significant differences were observed between NAC and AC, PC exhibited a substantial improvement in OS compared to both. Multivariate analysis highlighted chemotherapy timing as a prognostic factor for OS. Even after sIPTW, PC still demonstrated significantly longer OS compared to NAC and AC, and this trend persisted across almost all subgroups. Even after patients undergoing NAC and gastrectomy, AC remained essential. Notably, potential candidates exempt from AC were identified, including patients aged ≥65 years and those with tumor grades I-II.</p><p><strong>Conclusions: </strong>Chemotherapy timing was independent prognostic factors for resected GC. PC presented as a promising strategy, displaying superior OS compared to both NAC and AC. However, older individuals and those with well-differentiated tumors could considered exempt from further AC after receiving NAC and gastrectomy. Further research is needed to validate these findings and optimize GC management.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144546214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaping and Cancer Metastasis: Novel Preclinical Insights and Results from the All of Us Research Program.","authors":"Dhruv G Pillai, Cindy H Chau, Douglas K Price, William D Figg","doi":"10.1093/oncolo/oyaf190","DOIUrl":"https://doi.org/10.1093/oncolo/oyaf190","url":null,"abstract":"","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144531151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Molecular Tumor Board on Clinical Outcomes in Patients with Refractory Solid Tumor: a Real-World Study.","authors":"Yan Ling, Xiao-Dong Jiao, Bao-Dong Qin, Jiang-Shui Ding, Zhan Wang, Ke Liu, Wen-Xing Qin, Ying Wu, Li Sun, Dong-Min Shi, Shi-Qi Chen, Xue Zhong, Xiao-Peng Duan, Bing Li, Yuan-Sheng Zang","doi":"10.1093/oncolo/oyaf196","DOIUrl":"https://doi.org/10.1093/oncolo/oyaf196","url":null,"abstract":"<p><strong>Introduction: </strong>Providing precise oncologic treatment for patients with refractory solid tumor is still an unmet need in clinical practice. This study aimed to assess whether treatments recommended by a molecular tumor board (MTB) can improve clinical outcomes in patients with refractory solid tumors.</p><p><strong>Methods: </strong>We screened all patients with refractory solid tumor during the period from 2017 to 2022 at the authors' center. The patients with actionable molecular alterations (mainly included druggable tier 2 genetic variant identified using next-generation sequencing [NGS]) were presented to MTB. We compared the overall survival (OS) and progression-free survival (PFS) between the patients treated with a matched therapy recommended by MTB and those who did not receive the MTB-recommended therapy. Patients with no actionable molecular alterations served as an additional control.</p><p><strong>Results: </strong>A total of 338 patients with refractory solid tumor were screened. Among the 305 patients for whom NGS testing was conducted, 217 patients available for survival outcomes were included in the final analysis. A total of 129 patients had at least one actionable molecular alteration and were presented to MTB; 82 received the MTB-recommended therapy, while the remaining 47 did not. Those who received the recommended therapy had significantly longer median OS (17.7 vs. 4.4 months; HR 0.31, 95% CI 0.14-0.66; P < 0.001) and median PFS (7.0 vs. 2.3 months, HR 0.32, 95% CI 0.16-0.65; P < 0.001).</p><p><strong>Conclusion: </strong>MTB improves oncologic prognosis in patients with refractory solid tumor, and matching MTB-recommended therapy is an independent factor for OS and PFS.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144531143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Assessment in a Chinese Cohort of 96,318 Females Undergoing Opportunistic Cervical Cancer Screening.","authors":"Jing Zhao, Wenhan Li, Zehua Wang, Weichao Liu, Si Sun, Liying Wu, Shi Du, Guoqing Li, Zhongya Pan, Dingyu Chen, Pinglan Yang, Wuliang Wang, Liqiong Cai, Bangxing Huang, Jing Cai","doi":"10.1093/oncolo/oyaf197","DOIUrl":"https://doi.org/10.1093/oncolo/oyaf197","url":null,"abstract":"<p><strong>Objective: </strong>To assess CIN3+ risk in a Chinese cohort of outpatients undergoing contesting screening and to evaluate the portability of the ASCCP risk-based management, which were primarily developed using data from the KPNC cohort.</p><p><strong>Methods: </strong>Females aged 25-65 years who were screened with cytology and high-risk human papillomavirus (hrHPV) cotesting between 2011 and 2020 at Wuhan Union Hospital (WHUH) were retrospectively studied. The risks of immediate and 3-year CIN3+ were estimated via prevalence-incidence mixture models. Portability was evaluated via the ratio of the observation risk in the WHUH cohort to the expected risk in the KPNC cohort (O/E) and its 95% confidence interval (CI).</p><p><strong>Results: </strong>A total of 96,318 females were included, and 16·83% of the women tested hrHPV positive at initial screening, who had a CIN3+ immediate risk of 14·14%. The CIN3+ immediate risk varied between subgroups of positive HPV16 (34·09%), HPV18 (13·38%), other HPV types (6·71%), and negative hrHPV (0·12%). Compared to the KPNC cohort, our cohort exhibited a significantly higher CIN3+ immediate risk (1·42% vs. 0·46%; O/E, 3·09; 95% CI, 2·92-3·26) and disproportionately increased cancer immediate risks in most subgroups requiring immediate colposcopy or treatment, as well as higher 3-year CIN3+ risks in women with hrHPV negative ASC-US/NILM. Yet, the action threshold suggested by ASCCP, a CIN3+ immediate risk of 4%, showed good portability to our cohort.</p><p><strong>Conclusion: </strong>Despite the higher risks in our cohort, the ASCCP clinical action threshold remains portable. For women with minimal abnormalities or normal results, shortened follow-up intervals should be considered.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144531148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trastuzumab plus lapatinib or chemotherapy in patients with HER2-overexpressed advanced breast cancer: a randomized, phase II trial (GIM12-TYPHER).","authors":"Carmine De Angelis, Martina Pagliuca, Emanuela Magnolfi, Mauro Mansutti, Zelmira Ballatore, Michelino De Laurentiis, Roberto Bordonaro, Vita Leonardi, Dario Bruzzese, Roberta Caputo, Anna Maria Mosconi, Saverio Cinieri, Alessandra Fabi, Lucia Del Mastro, Fabio Puglisi, Sabino De Placido, Mario Giuliano, Grazia Arpino","doi":"10.1093/oncolo/oyaf200","DOIUrl":"https://doi.org/10.1093/oncolo/oyaf200","url":null,"abstract":"<p><strong>Background: </strong>Trastuzumab combined with chemotherapy is a standard treatment for HER2-positive advanced breast cancer in later lines. Lapatinib and trastuzumab have also demonstrated efficacy. This study assessed the efficacy, toxicity, and quality of life (QoL) of trastuzumab plus lapatinib (with endocrine therapy for hormone receptor-positive cases) versus trastuzumab with physician-selected chemotherapy in patients previously treated with at least two anti-HER2 regimens.</p><p><strong>Methods: </strong>In this open-label, multicenter phase II trial, 59 patients were randomized 1:1 to receive either trastuzumab and lapatinib (Arm A) or trastuzumab with chemotherapy (Arm B). The primary endpoint was clinical benefit rate (CBR), defined as confirmed complete response, partial response, or stable disease for ≥24 weeks. Secondary endpoints included overall survival (OS), progression-free survival (PFS), overall response rate (ORR), QoL, and safety.</p><p><strong>Results: </strong>With a median follow-up of 57.5 months, the CBR was 20.7% in Arm A and 26.7% in Arm B (p=0.76). The ORR was 13.8% vs. 20.0% (p=0.73), and median PFS was 3.6 months in Arm A vs. 6.1 months in Arm B (HR 0.63; p=0.08). Median OS was 29.9 vs. 31.1 months (HR 1.07; p=0.82). Adverse events occurred in 86.2% (Arm A) and 66.7% (Arm B) of patients, with grade 3-4 events in 24.1% and 13.3%, respectively. QoL favored Arm A (p=0.03). Due to early study closure and limited sample size, all results should be considered exploratory and not powered to assess definitive treatment effects.</p><p><strong>Conclusion: </strong>While efficacy differences were not significant, trastuzumab with lapatinib showed better QoL despite higher adverse event rates, suggesting it may be a viable chemotherapy-free option for pretreated HER2-positive advanced breast cancer.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144546215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utility And Real-World Clinical Outcomes Of Next-Generation Sequencing In Advanced Non-Small-Cell Lung Cancer In South Indian Population.","authors":"Anoop Tm, Lakshmi Raj, Pallavi Nair, Athira Vincent","doi":"10.1093/oncolo/oyaf168","DOIUrl":"https://doi.org/10.1093/oncolo/oyaf168","url":null,"abstract":"<p><strong>Background: </strong>Next-generation sequencing (NGS) is an advanced sequencing technology that enables rapid sequencing of numerous DNA strands and perform simultaneous analysis of various genes and diverse genomic characteristics. While there is a lack of substantial evidence available, the extent to which NGS may improve clinical outcomes among cancer patients in a real-world scenario remain uncertain.</p><p><strong>Objective: </strong>To investigate the clinical utility of NGS in patients treated with advanced non-small cell lung cancer (NSCLC) and its impact on real-world clinical outcomes, treated with targetable or non-targetable agents.</p><p><strong>Materials and methods: </strong>This was a prospective observational study conducted in 322 participants distributed over two broad categories- next-generation sequencing (NGS) and non-NGS. The NGS category consisted of patients who underwent genetic mutation screening by the NGS method. This group was further categorized into two sub groups- NGS - targetable and NGS- non targetable. The non- NGS category consisted of patients who did not undergo mutation testing by the NGS method.</p><p><strong>Results: </strong>There was a significant difference in overall survival between NGS and non-NGS groups (p=0.0038). There was a significant difference between NGS targetable and non- targetable groups in terms of PFS (p= 0.0016) and overall survival (OS) (p<0.0001). There was a significant difference between NGS- matched and non-matched groups in terms of PFS (p<0.00011) as well as OS (p<0.0001).</p><p><strong>Conclusion: </strong>NGS significantly improved survival in advanced NSCLC. Patients who received treatments matched to their NGS results experienced significantly longer survival compared to those with non-matched treatments.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144531150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary Neuroendocrine Tumors of the Breast According to the WHO 2019 Classification;Real Life Experiences of Rare Tumor Types of the Breast.","authors":"Seda Sali, Mursel Sali, Burcu Caner, Birol Ocak, Eyup Coban, Alper Coskun, Mine Ozsen, Sibel Oyucu Orhan, Ahmet Bilgehan Sahin, Adem Deligonul, Erdem Cubukcu, Sahsine Tolunay, Turkkan Evrensel","doi":"10.1093/oncolo/oyaf171","DOIUrl":"https://doi.org/10.1093/oncolo/oyaf171","url":null,"abstract":"<p><strong>Backround: </strong>Neuroendocrine neoplasms (NEN) originate in many body parts, with 70% reported from the gastrointestinal system, 25% from the lungs. NENs of the breast account for <1% of all NENs. The primary breast NEN nomenclature was changed in the most recent World Health Organization(WHO) classification in 2019. Since the pathological classification has changed several times, there are no definitive data on treatment management.</p><p><strong>Methods: </strong>In this study, patients followed up in our clinic were pathologically re-evaluated according to the latest classification.</p><p><strong>Results: </strong>The clinical characteristics, treatments, recurrence and survival status of 36 patients with early-stage primary breast NEN were examined. A statistically significant difference was determined in respect of overall survival (OS) for the Eastern Cooperative Oncology Group Performance Score (ECOG PS), type of surgery, age ≥ 70 years, PR positivity and tumor size. A low ECOG PS, younger age, breast-conserving surgery, and small tumor diameter were associated with better survival. A low ECOG PS, early stage, breast-conserving surgery, and fewer than four malignant lymph nodes were associated with better disease-free survival (DFS). All the patients in this study were at an early stage and were treated for typical breast cancer, although some patients diagnosed with neuroendocrine carcinoma (NEC) received cisplatin and etoposide treatment.</p><p><strong>Conclusion: </strong>In our study; the prognosis of breast NEN patients was better than the literature data. Maybe the prognosis of patients evaluated as breast NEN according to the new classification is better than the older classification groups.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144531145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}